FluBlok, a recombinant hemagglutinin influenza vaccine

Influenza and other Respiratory Viruses

Volumn 2, Issue 6, 2008, Pages 211-219

  Cox, Manon M J ^a   Patriarca, Peter A ^b   Treanor, John ^c  

^a Protein Sciences Corp   (United States)

^b BIOLOGICS CONSULTING GROUP INC   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Baculovirus; Cell culture; Hemagglutinin; Influenza; Safety; Vaccine

Indexed keywords

FLUBLOK; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO; TRIPLE VACCINE; UNCLASSIFIED DRUG; RECOMBINANT VACCINE;

ANTIBODY TITER; ARTHRALGIA; BACKACHE; CHILL; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG PURIFICATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; HYPERHIDROSIS; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSOMNIA; LIMB PAIN; MYALGIA; NAUSEA; NOSE CONGESTION; PAIN; PERICARDIAL EFFUSION; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SEROCONVERSION; SEX RATIO; SIDE EFFECT; SINGLE DRUG DOSE; SINUS CONGESTION; SINUSITIS; SKIN BRUISING; SKIN REDNESS; SORE THROAT; SWEATING; SWELLING; SYNCOPE; TOOTH ABSCESS; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ADULT; AGED; ANIMAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; PLACEBOS; UNITED STATES; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 58149327275     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00053.x     Document Type: Review

References (25)

1. Keitel WA, Couch RB, Cate TR et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994; 32:2468-2473.
2. Keitel WA, Cate TR, Atmar RL et al. Increased doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 1996; 3:507-510.
3. Wood JM. Standardization of Inactivated Influenza Vaccine; in Nicholson KG, Webster RG Hay AJ (eds): Textbook of Influenza. London: Blackwell Science, Ltd, 1998; 333-345.
4. Centers for Disease Control (CDC). ACIP. Prevention and control of influenza, recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report (MMWR) 2002; 51:1-31.
5. Huber VC, JA Cullers. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 2008; 10:75-85.
6. Lakey DL, Treanor JJ, Betts RF et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996; 174:838-841.
7. Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995; 171:1595-1599.
8. Powers DC, McElhaney JE, Florendo OA Jr et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from Influenza A (H3N2) virus. J Infect Dis 1997; 175:342-351.
9. Treanor JJ, Betts RF, Smith GE et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996; 173:1467-1470.
10. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans vaccine. Vaccine 2001; 19:1732-1737.
11. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-1351.
12. Goji NA, Nolan C, Hill H, Wolf M, Rowe T, Treanor JJ. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietman/1203/04 (H5N1 vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:629-631.
13. Treanor JJ, Schiff GM, Couch RB et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006; 193:1223-1228.
14. Safdar A, Rodriguez MA, Fayad LE et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: A double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 2006; 194:1394-1397.
15. Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. J Am Med Assoc 2007; 297:1577-1582.
16. Holtz KM, Anderson DK, Cox MM. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J 2003; 2:25-32.
17. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24:2176-2185.
18. Kida H, Webster RG, Yanagawa R. Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 1983; 76:91-99.
19. Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res 1986; 4:251-264.
20. Cox MM, Anderson DK. Production of a novel influenza vaccine using insect cells: Protection against drifted strains. Influenza Other Respir Viruses 2007; 1:35-40.
21. Protein Sciences Corporation. NCT00395174: Comparison of the Immunogenicity, Safety and Reactogenicity of FluBløk™, to a Licensed Vaccine in Elderly Adults. Bethesda, MD: National Institutes of Health, 2007. http://www.clinicaltrial.gov/ct2/show/NCT00395174?term= NCT00395174&rank=1 [accessed on 28 October 2008].
22. Protein Sciences Corporation. NCT00539981: Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and lot Consistency of FluBlok. Bethesda, MD: National Institutes of Health, 2007. http://www.clinicaltrial.gov/ct2/show/NCT00539864?term= NCT00539864&rank=1 [accessed on 28 October 2008].
23. Protein Sciences Corporation. NCT00539864: Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV. Bethesda, MD: National Institutes of Health, 2007. http://www.clinicaltrial.gov/ct2/show/NCT00539864?term= NCT00539864&rank=1 [accessed on 28 October 2008].
24. Renfrey S, Watts A. Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 1994; 12:747-752.
25. Hehme N, Engelmann H, Raderecht C, Porstmann T. Comparative Laboratory Results of Different Commercial Influenza Vaccines. Poster W07P-41. Option for the Control of Influenza V, Okinawa, Japan, 2003.